KeyBank National Association’s Royalty Pharma RPRX Stock Holding History

KeyBank National Association’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.07M	Buy	54,814 +9,420	+21%	+$490K	0.01%	391
2026 Q1	$2.18M	Buy	45,394 +6,668	+17%	+$292K	0.01%	436
2025 Q4	$1.5M	Buy	38,726 +3,514	+10%	+$134K	0.01%	500
2025 Q3	$1.24M	Buy	35,212 +2,073	+6%	+$75K	﹤0.01%	543
2025 Q2	$1.19M	Buy	33,139 +321	+1%	+$10.6K	﹤0.01%	539
2025 Q1	$1.02M	Buy	32,818 +4,666	+17%	+$148K	﹤0.01%	549
2024 Q4	$718K	Sell	28,152 -495	-2%	-$13.1K	﹤0.01%	654
2024 Q3	$810K	Buy	28,647 +5,114	+22%	+$142K	﹤0.01%	616
2024 Q2	$621K	Buy	+23,533	New	+$652K	﹤0.01%	665

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

KeyBank National Association's RPRX Position: Q2 2026 in Review

KeyBank National Association increased its Royalty Pharma (RPRX) stake by 21% in Q2 2026, buying an estimated $490K and bringing the position to 54,814 shares worth $3.07M. The position accounts for 0.01% of the portfolio, ranked #391.

KeyBank National Association first reported a position in RPRX in Q2 2024 and has held it in 9 quarters since. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

KeyBank National Association held 54,814 shares of Royalty Pharma worth $3.07M as of Q2 2026.
KeyBank National Association bought 9,420 Royalty Pharma shares in Q2 2026, an estimated $490K.
Royalty Pharma made up 0.01% of KeyBank National Association's portfolio in Q2 2026, its #391 holding.
KeyBank National Association first reported a position in Royalty Pharma in Q2 2024 and has held it in 9 quarters since.
647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on KeyBank National Association's 13F filing for Q2 2026, filed 28 Jul 2026.